ALKS | Alkermes plc

Index- P/E- EPS (ttm)-1.00 Insider Own1.75% Shs Outstand165.09M Perf Week4.18%
Market Cap5.01B Forward P/E20.20 EPS next Y1.50 Insider Trans-2.32% Shs Float161.64M Perf Month3.23%
Income-164.20M PEG- EPS next Q0.01 Inst Own99.60% Short Float / Ratio4.61% / 6.09 Perf Quarter12.43%
Sales1.12B P/S4.47 EPS this Y-223.30% Inst Trans-1.29% Short Interest7.46M Perf Half Y16.52%
Book/sh6.09 P/B4.99 EPS next Y1854.55% ROA-8.40% Target Price35.33 Perf Year3.72%
Cash/sh3.64 P/C8.34 EPS next 5Y24.80% ROE-15.70% 52W Range21.75 - 32.23 Perf YTD16.34%
Dividend- P/FCF- EPS past 5Y-1.70% ROI-10.00% 52W High-5.68% Beta0.60
Dividend %- Quick Ratio1.90 Sales past 5Y4.20% Gross Margin80.30% 52W Low39.77% ATR0.70
Employees2280 Current Ratio2.30 Sales Q/Q3.30% Oper. Margin-14.60% RSI (14)58.64 Volatility2.47% 2.15%
OptionableYes Debt/Eq0.29 EPS Q/Q-14.70% Profit Margin-14.70% Rel Volume1.14 Prev Close29.46
ShortableYes LT Debt/Eq0.29 EarningsApr 26 BMO Payout- Avg Volume1.23M Price30.40
Recom2.50 SMA200.72% SMA503.69% SMA20016.17% Volume1,401,592 Change3.19%
Date Action Analyst Rating Change Price Target Change
Nov-03-22Upgrade Piper Sandler Neutral → Overweight $26 → $30
Oct-14-22Upgrade BofA Securities Underperform → Neutral $27 → $25
Aug-16-22Initiated Piper Sandler Neutral $26
Apr-22-22Resumed Goldman Buy $35
Apr-20-22Initiated Goldman Buy $35
Jan-27-22Upgrade Cantor Fitzgerald Hold → Overweight $32
Dec-01-21Initiated Citigroup Neutral $22
Oct-07-21Upgrade Jefferies Hold → Buy $36
Sep-02-21Downgrade BofA Securities Neutral → Underperform $27
Oct-15-20Upgrade Mizuho Neutral → Buy $19 → $24
Jun-06-23 03:50PM
Jun-05-23 07:00AM
Jun-02-23 01:02PM
04:01PM Loading…
Jun-01-23 04:01PM
May-31-23 04:00PM
May-26-23 11:31AM
May-25-23 04:15PM
May-16-23 07:00AM
May-09-23 07:00AM
May-08-23 04:41PM
08:17AM Loading…
May-06-23 08:17AM
May-04-23 10:30AM
May-02-23 01:30PM
May-01-23 01:30PM
Apr-27-23 09:04AM
Apr-26-23 01:15PM
Apr-25-23 07:00AM
Apr-24-23 11:45AM
Apr-21-23 10:55AM
Apr-20-23 02:00PM
Apr-19-23 04:00PM
11:55AM Loading…
Apr-18-23 11:55AM
Apr-12-23 03:30PM
Mar-31-23 03:49PM
Mar-29-23 11:30AM
Mar-28-23 01:52PM
Mar-23-23 11:00AM
Mar-20-23 01:30PM
Mar-15-23 04:00PM
Mar-11-23 07:40AM
Feb-23-23 09:10AM
Feb-18-23 07:31AM
Feb-17-23 02:10PM
Feb-16-23 04:07PM
Feb-15-23 12:21PM
Feb-13-23 12:14PM
Feb-09-23 04:00PM
Feb-08-23 10:00AM
Feb-07-23 11:50AM
Feb-03-23 01:45PM
Feb-02-23 02:15PM
Jan-31-23 04:05PM
Jan-17-23 07:00AM
Jan-13-23 11:23AM
Dec-28-22 04:00PM
Dec-22-22 10:10AM
Dec-14-22 01:20PM
Dec-12-22 02:30PM
Dec-08-22 02:30PM
Dec-06-22 02:00PM
Dec-02-22 11:31AM
Dec-01-22 02:55PM
Nov-30-22 04:00PM
Nov-28-22 11:30AM
Nov-23-22 08:40AM
Nov-22-22 04:00PM
Nov-21-22 11:30AM
Nov-17-22 01:50PM
Nov-15-22 11:40AM
Nov-09-22 01:30PM
Nov-08-22 04:00PM
Nov-07-22 01:35PM
Nov-03-22 11:55AM
Nov-02-22 12:14PM
Nov-01-22 10:50AM
Oct-28-22 11:00AM
Oct-27-22 07:00AM
Oct-26-22 04:01PM
Oct-14-22 06:35PM
Oct-03-22 02:45PM
Sep-29-22 11:40AM
Sep-28-22 02:40PM
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA/ XEPLION for the treatment of schizophrenia and schizoaffective disorder; INVEGA TRINZA, TREVICTA, and HAFYERA/BYANNLI to treat schizophrenia; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nichols Christian ToddSVP, Chief Commercial OfficerMay 30Option Exercise20.4319,634401,12368,118May 30 08:16 PM
Nichols Christian ToddSVP, Chief Commercial OfficerMay 30Sale28.9327,134784,86240,984May 30 08:16 PM
Wysenski NancyDirectorMay 09Option Exercise31.1341,2501,284,11257,079May 10 04:34 PM
Wysenski NancyDirectorMay 09Sale31.2441,2501,288,78615,829May 10 04:34 PM
Daglio David Angelo Jr.DirectorNov 14Buy23.3135,000815,73480,000Nov 16 04:13 PM
Nichols Christian ToddSVP, Chief Commercial OfficerJun 21Sale28.267,474211,20321,035Jun 21 04:54 PM